Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784288 · ClinicalTrials.gov registry record · Phase 2
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02784288 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT02784288, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Investigators will determine whether a treatment paradigm of up-front neck dissection, to more accurately pathologically stage patients, minimizing the number of treatment modalities in patients with low risk oropharyngeal squamous cell carcinoma, can improve quality of life.
Interventions
- PROCEDURE Neck Dissection
- PROCEDURE Standard-of-Care (SOC) Transoral Surgery of Primary Site
- RADIATION SOC Radiation
- DRUG SOC Carboplatin
- DRUG SOC Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02784288
The ClinicalTrials.gov registry entry for NCT02784288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Neck Dissection is the first listed.
NCT02784288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02784288 about?
NCT02784288 is a clinical study titled "Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer". Investigators will determine whether a treatment paradigm of up-front neck dissection, to more accurately pathologically stage patients, minimizing the number of treatment modalities in patients with low risk oropharyngeal squamous cell carcinoma, can improve quality of life.
What is the current status of trial NCT02784288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2016-10-31. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT02784288?
The interventions under investigation include: Neck Dissection (PROCEDURE), Standard-of-Care (SOC) Transoral Surgery of Primary Site (PROCEDURE), SOC Radiation (RADIATION), SOC Carboplatin (DRUG), SOC Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02784288?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.